LXRX vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical while LXRX counters with relative strength in Options & Structure. Fundamentally, LXRX trades at N/M Forward P/E with -147.4% operating margin (-20.7% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LXRX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LXRX Revenue | DMAC Revenue | LXRX Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2015 | $130M | N/A | 1.1% | N/A | LXRX |
| FY2017 | $20M | N/A | -822.1% | N/A | LXRX |
| FY2018 | $30M | $0M | -388.5% | -1352.2% | LXRX |
| FY2019 | $30M | N/A | 437.5% | N/A | LXRX |
| FY2020 | $20M | N/A | -204.2% | N/A | LXRX |
| FY2023 | $0M | N/A | -15473.0% | N/A | LXRX |
| FY2024 | $10M | N/A | -3284.7% | N/A | LXRX |
| FY2025 | $50M | N/A | -98.2% | N/A | LXRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LXRX | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $810.3M | $503.1M | Larger Scale | LXRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -20.7% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | -147.4% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | -161.8% | 0.0% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -43.9% | -114.6% | Higher ROE | LXRX |
| 52-Week Range Position Momentum | 41% ($1โ$3) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 0.62ฮฒ ยท 60% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | LXRX |
| Unified Institutional Score Composite Signal | 38.7 / 100 (SELL) | 46.3 / 100 (HOLD) | Higher Composite | DMAC |